Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Yahoo! Finance
– Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 with cash, cash equivalents, and investments of $269.6 million; Cash runway expected into 2026 – Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today reported financial results and business highlights for the second quarter ended June 30, 2024. “Our strategic autoimmune expansion, as highlighted by the recent initiation of the CALiPSO-1 trial in Systemic Lupus Erythematosus and addition of a Lupus Nephritis-specific cohort, positions Century as a potential leader in allogeneic cell therapies for autoimmune diseases. 2024 remains a time of f
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics, Inc. (NASDAQ: IPSC) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- After losing 17% in the past year, Century Therapeutics, Inc. (NASDAQ:IPSC) institutional owners must be relieved by the recent gain [Yahoo! Finance]Yahoo! Finance
IPSC
Earnings
- 5/9/24 - Beat
IPSC
Sec Filings
- 9/16/24 - Form 4
- 8/8/24 - Form 8-K
- 8/8/24 - Form 10-Q
- IPSC's page on the SEC website